Development Pipeline

Select programs in development, Phase 1 through Approval (removed after programs achieve approval in both US/EU)

Learn More

Novel Therapies

Select Novel Therapy programs recently approved or with potential filings in the US/EU within a specified window as outlined in the Pharmaceutical Business Review.

Learn More

2023 Key Events

Major US/EU Approvals and Submissions and Phase 2/3 Clinical Data presentations being planned or achieved for the year.

Learn More

U.S. Patent Expiry Tables

Information about our pharmaceutical patent portfolio.

Learn More

Contact Investor Relations

Questions? Please contact us: